[Association of genetic variant in 12-lipoxygenase and risk of hepatic carcinoma].
To explore the association of 12-lipoxygenase (LOX12) Arg261Gln polymorphism with the risk of hepatic carcinoma in Chinese population. A total of 280 cases of hepatic carcinoma and 560 frequency-matched controls were recruited from January 2008 to December 2012 at Hebei United University Affiliated Hospital. The method of PCR-restriction fragment length polymorphism (RFLP) was employed to genotype LOX12 Arg261Gln polymorphism. And odds ratios (OR) and 95% confidence intervals (CI) were calculated with a model of unconditional Logistic regression. The allelic frequency for LOX12 Arg261Gln was significantly higher in hepatic carcinoma cases than that in controls (0.563 vs 0.437). For the control group, the three genotypes of LOX12 Arg/Arg, Arg/Gln and Gln/Gln were 24.3% (136/560), 52.9% (296/560) and 22.8% (128/560) respectively. For the hepatic carcinoma group, these three genotypes were 19.1% (53/278), 49.3% (137/278) and 31.6% (88/278) respectively. Logistic regression analysis showed that, compared with 261 Arg/Arg genotype carriers, the subjects with 261Gln/Gln had increased risks for hepatic carcinoma (OR = 1.83, 95%CI:1.18-2.84). When stratified by smoking status, the 261Gln/Gln carriers had an increased risk of developing hepatic carcinoma (OR = 2.23, 95%CI:1.16-4.26) among smokers, but not among non-smokers. LOX12 Arg261Gln polymorphism is associated with the susceptibility to hepatic carcinoma.